Barclays PLC Citius Pharmaceuticals, Inc. Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 94,468 shares of CTXR stock, worth $50,068. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,468

Previous 168,823 44.04%

Holding current value

$50,068

Previous $128,000 33.59%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.6 - $0.9 $44,613 - $66,919	-74,355 Reduced 44.04%	94,468 $85,000
Q4 2023 Feb 15, 2024	BUY	$0.65 - $0.86 $95,574 - $126,451	147,037 Added 674.92%	168,823 $128,000
Q3 2023 Nov 07, 2023	SELL	$0.65 - $1.25 $1,762 - $3,388	-2,711 Reduced 11.07%	21,786 $15,000
Q2 2023 Aug 03, 2023	BUY	$1.08 - $1.65 $26,456 - $40,420	24,497 New	24,497 $29,000
Q3 2022 Nov 03, 2022	SELL	$0.14 - $1.33 $449 - $4,271	-3,212 Reduced 48.7%	3,383 $4,000

Q2 2022 Aug 12, 2022	SELL	$0.88 - $1.87 $11,894 - $25,276	-13,517 Reduced 67.21%	6,595 $6,000
Q1 2022 May 16, 2022	SELL	$1.38 - $1.89 $162,452 - $222,488	-117,719 Reduced 85.41%	20,112 $36,000
Q4 2021 Feb 14, 2022	BUY	$1.51 - $2.2 $138,051 - $201,135	91,425 Added 197.01%	137,831 $212,000
Q3 2021 Nov 09, 2021	SELL	$1.74 - $2.6 $10,734 - $16,039	-6,169 Reduced 11.73%	46,406 $94,000
Q2 2021 Aug 13, 2021	BUY	$1.51 - $4.23 $65,277 - $182,862	43,230 Added 462.6%	52,575 $183,000
Q1 2021 May 13, 2021	BUY	$1.04 - $2.34 $9,718 - $21,867	9,345 New	9,345 $17,000
Q1 2020 May 13, 2020	SELL	$0.46 - $1.3 $5 - $14	-11 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$0.42 - $1.15 $4 - $12	11 New	11 $0

Others Institutions Holding CTXR

# of Institutions

Shares Held

26.8M

Call Options Held

Put Options Held

View Full List

About Citius Pharmaceuticals, Inc.

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $77.4M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

More about CTXR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account